Novo Nordisk (NVO) has laid off dozens of employees at the largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs, a Reuters review of LinkedIn posts shows, Maggie Fick and Soren Jeppesen report. The cuts include staff in manufacturing roles, from quality control to production line technicians, at Novo’s major Clayton, North Carolina, plant and other facilities in the state, according to the report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s Stock Surges Amid Drug Discounts
- Costco (COST) Will Sell Discounted Ozempic and Wegovy for Those without Insurance
- Moderately bullish activity in Novo Nordisk with shares down 0.92%
- Novo Nordisk upgraded to Buy from Hold at HSBC (yesterday)
- Analysts Reaffirm Buy Ratings on Pfizer Stock (PFE) after Trump Pricing Deal